Asosiy kontentga oʻtish
Maqola

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial

Paul M. RidkerCenter for Cardiovascular Disease Prevention, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USAEleanor DanielsonHarvard UniversityFrancisco Antônio Helfenstein FonsecaUniversidade Federal de Sao Paulo, Sao Paulo, BrazilJacques GenestMcGill University Health Center, Montreal, Quebec, CanadaAntonio M. GottoWeill Cornell Medical College of Cornell University, New York, NY, USAJohn J.P. KasteleinUniversity of AmsterdamWolfgang KöenigUniversity of Ulm Medical Center, Ulm, GermanyPeter LibbyDivision of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USAAlberto LorenzattiHospital Cordoba, Cordoba, ArgentinaJean MacFadyenCenter for Cardiovascular Disease Prevention, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USABørge G. NordestgaardHerlev Hospital, Copenhagen University Hospital, Herlev, DenmarkJames ShepherdUniversity of Glasgow, Glasgow, UKJames T. WillersonSt Luke's Episcopal Hospital/Texas Heart Institute, Houston, TX, USARobert J. GlynnCenter for Cardiovascular Disease Prevention, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
2009en

Ochiq kirish: yoʻq

ABI

Annotatsiya

Annotatsiya mavjud emas.

Identifikatorlar

Iqtiboslar va manbalar

2 ta iqtibos0 ta foydalanilgan manba